RISER Meet and Greet
ID: 75D30125R73218Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Original Source

https://sam.gov/opp/2ff3b23bac4b491cbaef4cd5922e1002/view
Timeline
    Description

    The Centers for Disease Control and Prevention (CDC) is seeking qualified large businesses under NAICS 325413, In-Vitro Diagnostic Substance Manufacturing, to participate in the RISER Meet and Greet initiative aimed at enhancing public health surveillance and laboratory capacity. This opportunity is part of a phased approach to identify capable businesses that can provide diagnostic and testing services, ultimately expanding the CDC's inventory of reference pathogens and detection kits for rapid response during public health emergencies. Interested parties must respond by November 14, 2024, with their capabilities and relevant past performance, as the virtual meet-and-greet conference is scheduled for December 11, 2024. For further inquiries, interested businesses can contact Jennifer Gartzke at jgartzke@cdc.gov or call 404-498-0020.

    Point(s) of Contact
    Jennifer Gartzke
    (404) 498-0020
    jgartzke@cdc.gov
    Files
    Title
    Posted
    RISER Meet and Greet Announcement Phase I.pdf
    The CDC's Resources for Improvement of Surveillance and Emergency Response (RISER) aims to enhance public health surveillance and laboratory capacity by engaging large and small businesses through a phased approach. Phase I calls for interested large businesses in diagnosing and testing services, specifically under NAICS 325413. Interested parties must respond by November 14, 2024, indicating their capabilities and relevant past performance. The initiative is structured into three phases: identifying large businesses, inviting small businesses for collaboration, and conducting a virtual meet-and-greet conference scheduled for December 11, 2024. The goal is to expand the previous CDC Influenza Reagent contract to generate a robust inventory of reference pathogens, detection kits, and assays to enable fast responses during public health emergencies. To support these efforts, the contractor will need to maintain strict quality control over reagents, ensure compliance with federal guidelines, and manage a transparent operation for reagent distribution. The successful operation will include extensive documentation procedures, real-time inventory tracking, and adherence to safety standards. Overall, this program aligns with national strategies to bolster U.S. health security amid rising health threats.
    Lifecycle
    Title
    Type
    RISER Meet and Greet
    Currently viewing
    Special Notice
    Similar Opportunities
    National Health and Nutrition Examination Survey (NHANES) General Chemistry Laboratory Testing
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), is seeking qualified Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories to provide General Chemistry Laboratory Testing services for the National Health and Nutrition Examination Survey (NHANES). The objective of this procurement is to perform biochemical analyses on approximately 20,000 biological samples collected during the survey, focusing on health conditions such as kidney, liver, and heart diseases, while ensuring timely reporting of results within three weeks of sample receipt. This initiative is crucial for gathering national health statistics and maintaining public health surveillance, emphasizing the importance of data integrity and confidentiality in compliance with federal regulations. Interested organizations must submit their capabilities and relevant documentation by November 7, 2024, to the designated contacts, David Santimaw and Arianna Williams, at the CDC.
    Notice of Intent to Sole Source - Biosearch Technologies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) intends to negotiate a sole source contract with Biosearch Technologies, Inc. for the production of proprietary PCR kits essential for the Laboratory Response Network (LRN). The procurement aims to ensure a consistent supply of reagents necessary for detecting biothreat agents and emerging infectious diseases, which are critical for national preparedness and response capabilities. These kits, which must comply with FDA quality standards, are vital for high-security laboratories and are designed to identify various bioterrorism agents. Interested parties may submit capability statements or proposals to Matthew Nelson at mnelson2@cdc.gov by November 7, 2024, at 3:30 PM EST for consideration.
    Serological Assays for the detection and characterization of influenza viruses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for the provision of serological assays aimed at detecting and characterizing influenza viruses. This contract encompasses a 12-month base period with four additional 12-month option periods, focusing on testing immunological responses from human samples collected during vaccine effectiveness studies, randomized controlled trials, and outbreak investigations using Hemagglutination Inhibition (HAI) assays. The services are critical for understanding vaccine efficacy and managing influenza outbreaks, with the government supplying necessary standard operating procedures, proficiency panels, and controls to ensure proper assay performance. Interested parties should contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further details, as this opportunity is set aside for small businesses under the SBA guidelines.
    Sources Sought-BioFire Reagents and Test Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is conducting a Sources Sought announcement to identify potential qualified small businesses capable of supplying BioFire Defense reagents and test kits. The NIH's Department of Laboratory Medicine requires these reagents for their BioFire FilmArray analyzers, which are essential for the rapid detection of infectious agents from clinical samples, thereby facilitating timely treatment. Interested vendors must submit their company information, including a capability statement, by 12:00 PM EST on November 7, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the government will not reimburse any costs associated with this request.
    RFI for World Trade Center Health Program (WTCHP) Mental Health Evaluation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), is seeking qualified vendors to respond to a Request for Information (RFI) aimed at developing a specialized mental health provider network for the World Trade Center Health Program (WTCHP). The primary objective is to address the unique mental health needs of WTCHP members, particularly those affected by 9/11-related conditions, by ensuring timely access to outpatient services and integrating these services with existing care teams while overcoming challenges such as provider shortages and billing complexities. This initiative is crucial for enhancing the quality of care and service delivery for individuals impacted by the events of September 11, 2001. Interested parties are encouraged to submit their responses detailing their experience and proposed solutions by contacting Eugenia J. Corder at xvn9@cdc.gov or by phone at 404-498-4855. This RFI is for information and planning purposes only and does not constitute a solicitation for proposals.
    Pediatric Flu Vaccine – 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking proposals for the procurement of pediatric influenza vaccines for the 2025-2026 season under solicitation number 75D301-25-R-73215. The CDC requires one or more indefinite quantity, indefinite delivery contracts for the purchase of vaccines specifically for children aged 0 through 18 years, with a minimum order size of 100 doses and a maximum of 30 million doses, to support immunization programs under the Vaccine for Children (VFC) program. This initiative is crucial for enhancing public health by ensuring the availability of quality vaccines to reduce healthcare costs associated with preventable diseases. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov.
    Adult Flu Vaccines 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is soliciting proposals for Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to procure adult influenza vaccines for the 2025-2026 season. The procurement aims to utilize Section 317 vaccine purchase funds to provide state and local health departments with access to vaccines at favorable prices, particularly targeting populations at higher risk of under-vaccination. This initiative includes a minimum order of 100 doses and a maximum of 6 million doses, with strict compliance to FDA standards and specific delivery requirements. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov. The contract period will extend from the date of award through February 28, 2026.
    RFI-Transportable Patient Biocontainment, Isolation, and Quarantine Systems
    Active
    Dept Of Defense
    The U.S. Department of Defense seeks innovative solutions for its Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN Protection) program. The requirement is for transportable biocontainment, isolation, and quarantine (BIQ) systems, or components thereof, to be used across various platforms such as ships, aircraft, wheeled vehicles, and field deployable systems. These systems are crucial in preventing the spread of biological threats and addressing public health emergencies. Modularity, scalability, and compatibility with existing healthcare infrastructure are key attributes the government seeks, along with strict adherence to safety and quality standards. The focus is on finding deployable and sustainable solutions to contain hazardous pathogens, with the potential for multiple system applications across different platforms. An upcoming Innovation Day on October 9th, 2024, will provide an opportunity for interested parties to discuss their technologies and gain a deeper understanding of the government's requirements. Per the request, responses must be submitted via email to Brian Liska at brian.liska@usmc.mil by November 8th, 2024, at 5:00 p.m. EST. The contact email is brian.liska@usmc.mil, and further details can be found on the SAM.gov website.
    BD Biosciences Proprietary Instrumentation Package and Reagent Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure a proprietary instrumentation package and reagent kits from Becton, Dickinson & Company for the Department of Laboratory Medicine. This acquisition aims to secure essential supplies, including instrument rentals and quality control materials, necessary for the operation of the Hematology Flow Cytometry Service, which plays a critical role in patient care and research. The procurement is vital for maintaining the laboratory's capacity to deliver timely and accurate results, as the specified reagent kits are uniquely compatible with the existing BD Rhapsody™ single cell analysis system. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by November 14, 2024, at 6:30 AM EST, as this is a presolicitation notice and not a request for quotations.
    RFI - World Trade Center (WTC) Health Program's Medical Coding System Transition
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking insights from qualified organizations regarding the transition of the World Trade Center (WTC) Health Program's medical coding system from ICD-9 to ICD-10 and beyond. The primary objective of this Request for Information (RFI) is to identify effective methods for automating updates to member certification files, ensuring alignment with valid ICD codes to maintain the integrity of the certification process for 9/11 Responders and Survivors. This initiative is crucial for ensuring continued access to necessary healthcare services for individuals affected by the events of September 11, 2001, as established under the James Zadroga 9/11 Health and Compensation Act of 2010. Interested parties are invited to submit a white paper by November 26, 2024, detailing their experience and capabilities related to coding transitions, with inquiries directed to Laurie Presley at xnp0@cdc.gov.